Clinical Trials

62 studies in Neurology - Enterprise

  1. Neuroblastoma Biology Studies
    1. Minnesota
  2. A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer s Disease (Protocol No. MK-8931-017-08)(Also Known as SCH 900931, P07738)
    1. Arizona
  3. Longitudinal Study of Cognition With Niemann-Pick Disease, Type C
    1. Minnesota
  4. Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
    1. Minnesota
  5. Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
    1. Minnesota
  6. Natural History and Biospecimen Repository for Dystonia; Comprehensive Rating Tools for Cervical Dystonia; Validity & Reliability of Diagnostic Methods & Measures of Spasmodic Dysphonia
    1. Arizona
  7. Ultrasound-guided Greater Occipital Nerve Injection at Novel Proximal Location: A Clinical Series
    1. Minnesota
  8. PiB PET Scanning in Speech and Language Based Dementias
    1. Minnesota
  9. An Open Label, Multicenter Study, Evaluating the Safety and Efficacy of 18F-AV-133 PET Imaging to Identify Subjects With Dopaminergic Degeneration Among Subjects Presenting to a Movement Disorders Specialty Clinic With an Uncertain Diagnosis
    1. Arizona
  10. A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial
    1. Minnesota
  1. Prev
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. Next

Clinical Trials

62 studies in Neurology - Enterprise

  1. Neuroblastoma Biology Studies
    1. Minnesota
  2. A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer s Disease (Protocol No. MK-8931-017-08)(Also Known as SCH 900931, P07738)
    1. Arizona
  3. Longitudinal Study of Cognition With Niemann-Pick Disease, Type C
    1. Minnesota
  4. Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
    1. Minnesota
  5. Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
    1. Minnesota
  6. Natural History and Biospecimen Repository for Dystonia; Comprehensive Rating Tools for Cervical Dystonia; Validity & Reliability of Diagnostic Methods & Measures of Spasmodic Dysphonia
    1. Arizona
  7. Ultrasound-guided Greater Occipital Nerve Injection at Novel Proximal Location: A Clinical Series
    1. Minnesota
  8. PiB PET Scanning in Speech and Language Based Dementias
    1. Minnesota
  9. An Open Label, Multicenter Study, Evaluating the Safety and Efficacy of 18F-AV-133 PET Imaging to Identify Subjects With Dopaminergic Degeneration Among Subjects Presenting to a Movement Disorders Specialty Clinic With an Uncertain Diagnosis
    1. Arizona
  10. A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial
    1. Minnesota
  1. Prev
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. Next
.

Mayo Clinic Footer